"通络养生八字经"互动区更是吸引了不同年龄层的观众踊跃参与。融汇"儒、释、道、医"养生智慧与现 代生命科学，这一创新理论强调气血畅通、营养免疫、科学运动、心理健康的协同，为健康管理提供系 统方案。目前，以岭药业已开发出十余种具有独家专利的亚健康调理产品，储备百余种产品概念，成为 中医药产业向大健康领域延伸的生动实践。 近日，第三届中国国际供应链促进博览会（以下简称"链博会"）在北京举办。本届链博会以"链接世界 共创未来"为主题，设置了先进制造链、清洁能源链、智能汽车链、数字科技链、健康生活链、绿色农 业链六大链条和供应链服务展区。来自75个国家和地区的650余家企业和机构积极参展，其中境外参展 商占比达35%。 在健康生活链展馆中，多家医药健康领域头部企业齐聚，围绕理论突破、科研创新、产业实践、国际化 发展等多元主题，分享了拳头产品矩阵、服务升级理念、学术交流成果等优秀案例，共促大健康产业高 质量发展。 以岭药业 中医药创新链 激发科研与产业新动能 作为中医药行业头部企业，在本次链博会上，以岭药业从夯实产业链、激活创新链、延伸健康链、学术 链接世界等多个方面展示了其推动中医药高质量发展的丰硕成果。 为夯实产业 ...

证券代码：600332 证券简称：白云山 公告编号：2025-053 广州白云山医药集团股份有限公司 关于子公司获得药品补充申请批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"）子 公司广州白云山陈李济药厂有限公司（以下简称"陈李济药厂"）收到国 家药品监督管理局（以下简称"国家药监局"）签发的《药品补充申请批 准通知书》。现将有关情况公告如下： 一、药品的基本情况 生产企业：（1）名称：广州白云山陈李济药厂有限公司；（2）地址： 广州市海珠区广州大道南 1688 号 申请内容：变更药品规格 1 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准本品变更药品规格的补充申请，同意 增加小蜜丸规格，规格：每 40 丸重 10g（每 1g 相当于饮片 0.52g），有 效期：24 个月。 药品通用名称：千金保孕丸 剂型：丸剂（小蜜丸） 通知书编号：2025B01053 受理号：CYZB2401460 药品注册标准编号：Y ...

白云山（600332）公告，子公司陈李济药厂收到国家药监局签发的《药品补充申请批准通知书》。药品 通用名称为千金保孕丸，剂型为丸剂(小蜜丸)，通知书编号为2025B01053，受理号为CYZB2401460，药 品注册标准编号为YBZ00162025。原药品批准文号为国药准字Z44022637。申请内容为变更药品规格， 审批结论为批准本品变更药品规格的补充申请，同意增加小蜜丸规格，规格：每40丸重10g(每1g相当于 饮片0.52g)，有效期：24个月。 ...

Group 1 - Haitong Development reported a net profit of 86.87 million yuan for the first half of 2025, a year-on-year decrease of 64.14% [1] - Haitong Development achieved an operating income of 1.8 billion yuan, a year-on-year increase of 6.74% [1] - Crystal Integrated expects a net profit increase of 39.04% to 108.55% for the first half of 2025, with projected revenue between 5.07 billion yuan and 5.32 billion yuan [1] Group 2 - Aerospace Universe anticipates a net profit increase of 50.59% for the first half of 2025, with a projected net profit of 34.38 million yuan [2] - Aerospace Universe's net profit excluding non-recurring gains is expected to grow by 94.90% [2] Group 3 - Guodian Power reported a total power generation of 206.03 billion kWh for the first half of 2025, a year-on-year decrease of 3.61% [3] - The company's market-based transaction electricity accounted for 91.84% of the total electricity sold [3] Group 4 - Shanghai Pharmaceuticals announced that its tranexamic acid injection has passed the consistency evaluation for generic drugs [5] - The drug is primarily used for treating various bleeding disorders [5] Group 5 - Sanyou Chemical received approval to issue up to 900 million yuan in technology innovation corporate bonds [7] - The bond issuance is valid for 24 months from the date of approval [7] Group 6 - Baiyuntian's BAT4406F injection drug has received approval for clinical trials for additional indications [9] - The drug is a next-generation fully human anti-CD20 antibody [9] Group 7 - Huason Pharmaceutical received three drug re-registration approval notices [10] - The approved drugs include Ganji Bingmei tablets and other formulations [10] Group 8 - Shanying International plans to establish the Zhiyuan Fund with a total scale of 100 million yuan [13] - The fund will primarily invest in product companies related to industrial scenarios [13] Group 9 - Yiqiu Resources announced the sale of two properties in Malaysia for a total of approximately 3.67 million yuan [15] - The sale is part of the company's asset management strategy [15] Group 10 - Guizhou Bailing plans to apply for loans totaling no more than 920 million yuan from multiple banks [16] - The loans will be used to replace maturing loans and supplement working capital [16] Group 11 - Samsung Medical's subsidiary won a transformer procurement contract in Brazil worth approximately 341 million yuan [16] - The contract is part of the company's expansion into international markets [16] Group 12 - Changying Tong expects a net profit increase of 72.12% to 110.33% for the first half of 2025 [17] - The projected revenue is between 173 million yuan and 211 million yuan [17] Group 13 - Canqin Technology anticipates a net profit increase of 50.14% to 61.85% for the first half of 2025 [17] - The expected revenue is between 286 million yuan and 290 million yuan [17] Group 14 - Daya Shengxiang signed a lease agreement with an annual rent of 17 million yuan for a production facility [18] - The lease term is for 3 years and 4 months, including a 4-month rent-free period [18] Group 15 - Zhongzai Zihuan announced the resignation of its general manager due to work adjustments [20] - The company will appoint an interim general manager while searching for a permanent replacement [20] Group 16 - Fuwei Co. received a project notification from a well-known luxury brand for seat development [22] - The total sales amount for the project is expected to reach 4.9 billion yuan [22] Group 17 - Meili Technology's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [26] - The issuance is subject to further approval from regulatory authorities [26] Group 18 - Jinzhik Technology announced a stock suspension due to potential control changes [27] - The suspension is expected to last no more than two trading days [27] Group 19 - Zhongtian Technology plans to distribute a cash dividend of 3 yuan per 10 shares [28] - The dividend distribution date is set for July 25, 2025 [28] Group 20 - Huahai Chengke plans to distribute a cash dividend of 0.2002 yuan per share [30] - The dividend distribution date is set for July 29, 2025 [30] Group 21 - Dasheng Intelligent won a smart transportation project contract worth 122 million yuan [31] - The project involves comprehensive monitoring systems for urban rail transit [31] Group 22 - Dongyue Silicon reported a fire incident affecting production operations [32] - The fire has been controlled, but the extent of damage is still being assessed [32] Group 23 - Shaanxi Guotou A reported a net profit of 726 million yuan for the first half of 2025, a year-on-year increase of 5.74% [35] - The company's operating income decreased by 2.95% [35] Group 24 - Yibo Technology announced a plan to reduce shareholding by up to 3% [37] - The reduction is due to the shareholder's funding needs [37] Group 25 - Xiling Information announced a stock suspension due to potential control changes [39] - The suspension is expected to last no more than two trading days [39] Group 26 - Tianli Lithium Energy plans to reduce shareholding by 4.55% through block trading [40] - The reduction is due to the fund's operational timeline nearing its end [40] Group 27 - Sihui Fushi announced plans for a combined shareholding reduction of up to 3% [42] - The reduction is due to the shareholders' personal funding needs [42] Group 28 - Jinma Leisure announced a plan for a combined shareholding reduction of up to 4.83% [44] - The reduction is due to personal funding needs of the controlling shareholder and executives [44] Group 29 - *ST Zitian's stock may be terminated due to financial reporting issues [46] - The company is under regulatory scrutiny for failing to rectify its financial statements [46]

证券代码：600332 证券简称：白云山 公告编号：2025－052 广州白云山医药集团股份有限公司 关于分公司收到药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 分公司广州白云山医药集团股份有限公司白云山制药总厂（以下简称 "白云山制药总厂"）收到国家药品监督管理局核准签发关于盐酸曲 美他嗪缓释片（35mg）的《药品注册证书》。现将相关情况公告如下： 一、药品的基本情况 药品通用名称：盐酸曲美他嗪缓释片 剂型：片剂 规格：35mg 注册分类：化学药品 4 类 证书编号：2025S02152 药品注册标准编号：YBH16172025 上市许可持有人：（1）名称：广州白云山医药集团股份有限公 司白云山制药总厂；（2）地址：广州市白云区同和街云祥路 88 号 生产企业：（1）名称：广州白云山医药集团股份有限公司白云 山制药总厂；（2）地址：广州市白云区同和街云祥路 88 号 受理号：CYHS2400195 药品批准文号：国药准字 H20254831 药 ...

Group 1 - The event "Inheriting Good Family Traditions and Good Family Values" organized by Baiyunshan Xiaochaihu celebrated its 8th anniversary, combining traditional Chinese medicine culture with family values [4][12] - The event took place at the Lingshou City Cultural Square in Jinan, featuring various traditional elements and modern vitality, attracting many local residents [4][16] - The event included family story-sharing sessions, where families shared their unique family values, emphasizing the importance of moral education and daily practice [5][18] Group 2 - Interactive segments such as audience Q&A and dialect games were included, allowing participants to engage and learn about traditional Chinese medicine in a fun atmosphere [9][11] - The event highlighted Baiyunshan Xiaochaihu's commitment to social responsibility through various initiatives, including pandemic donations and cultural inheritance [12][18] - The leaders' speeches during the event called for families to work together to promote good family values and spread positive social energy [16][18]

Core Points - The event "Inheriting Good Ancient Recipes, Inheriting Good Family Traditions" by Baiyunshan Xiaochaihu marks its 8th anniversary and aims to promote positive family values in Shandong [1][2] - The event was live-streamed on social media platforms, achieving over 1.14 million views [2] - Baiyunshan Xiaochaihu has been actively involved in social responsibility initiatives, including donations exceeding 10 million yuan for various causes [7] Group 1 - The event was held in Jinan, Shandong, and is part of a broader initiative to spread love and positive energy through family values [1][2] - Baiyunshan Xiaochaihu has organized this event across 12 provinces over the past eight years, sharing over 200 stories of good family traditions [6][15] - The event featured participation from various local leaders and organizations, highlighting community collaboration [6][21] Group 2 - Baiyunshan Xiaochaihu announced a new initiative called "One More Penny of Care," where a portion of sales will be donated to public welfare projects [16] - The company received a gold award at the 50th Geneva International Exhibition for its innovative Xiaochaihu granules, showcasing its commitment to modernizing traditional medicine [15] - The upgraded national standard for Xiaochaihu granules has been included in the 2025 edition of the Chinese Pharmacopoeia, reflecting industry recognition [15] Group 3 - The event included performances and cultural displays, emphasizing the rich cultural heritage of Shandong [24][27] - Families sharing their good family traditions were recognized, reinforcing the importance of family values in society [20][30] - Baiyunshan Xiaochaihu plans to continue its "Finding Good Family Traditions" initiative to enrich cultural life and promote social virtues [30]

Core Viewpoint - A recent network meta-analysis published in a core journal indicates that Baiyunshan Gushen Dingchuan Wan shows superior efficacy in improving clinical effectiveness and forced vital capacity (FVC) for treating stable chronic obstructive pulmonary disease (COPD) [2][3][9]. Group 1: Research Findings - The study reviewed randomized controlled trials of oral traditional Chinese medicine for stable COPD treatment, utilizing a network meta-analysis approach [6][7]. - Results demonstrated that five types of oral traditional Chinese medicines significantly improved treatment outcomes with a high safety profile and minimal adverse reactions [8][9]. - Among the evaluated medicines, Gushen Dingchuan Wan exhibited the best performance in enhancing clinical effectiveness and FVC [9]. Group 2: Treatment Mechanism - Gushen Dingchuan Wan is formulated based on principles of warming the kidneys and lungs, and strengthening the spleen to alleviate symptoms in COPD patients with kidney and lung qi deficiency [10][13]. - The medicine aims to improve lung function and promote respiratory muscle recovery, thereby enhancing patient vitality and quality of life [11][14]. Group 3: Clinical Guidelines and Recommendations - Gushen Dingchuan Wan is included in several authoritative guidelines and consensus recommendations for COPD treatment, such as the "Clinical Application Guidelines for Integrated Traditional and Western Medicine in COPD (2024)" [16][17]. - Its inclusion in these guidelines supports its further application and promotion in the treatment of related diseases [20].

Core Viewpoint - The 2025 China Clinical Oncology Annual Progress Seminar (BOC) and Best of ASCO® 2025 China will be held on July 4-5, 2025, focusing on significant research findings from the ASCO annual meeting and enhancing the influence of Chinese scholars in the international arena [2]. Group 1: Clinical Research Findings - The IV phase clinical study led by Professor Liu Zhigang on "Baiyunshan Nasopharyngeal Detox Granules" demonstrated significant improvements in severe nasal secretion symptoms and reduced the incidence of severe oral mucositis in nasopharyngeal cancer patients undergoing radiotherapy, indicating a promising innovative treatment option [2]. - The study also reported improvements in symptoms such as throat pain and dryness, showcasing good safety profiles for the treatment [2]. Group 2: Background and Development - Radiotherapy remains the primary curative method for nasopharyngeal cancer, with approximately 90% of patients experiencing adverse reactions like radiation-induced oral mucositis, which severely impacts treatment outcomes and quality of life [3]. - Baiyunshan and Huang Zhong Medicine have invested in clinical research since 2022 to address radiation-induced damage in the nasopharyngeal area, with the project supported by prominent experts in the field [3][4]. - Baiyunshan Nasopharyngeal Detox Granules, developed in collaboration with Sun Yat-sen University Cancer Center and Guangzhou Pharmaceutical Group, is clinically used for chronic inflammation and increased secretion symptoms post-radiotherapy [4].

Group 1 - The Artemisinin concept index increased by 0.65%, ranking 10th among concept sectors, with four stocks rising, including Haizheng Pharmaceutical which hit the daily limit, and Zhejiang Medicine, Huaren Shuanghe, and Baiyunshan also showing gains of 0.79%, 0.69%, and 0.08% respectively [1] - The leading decliners in the sector included Rundu Co., New Harmony, and Kunming Pharmaceutical, which fell by 1.41%, 1.36%, and 1.17% respectively [1] - The net inflow of main funds into the Artemisinin concept sector was 95 million yuan, with Haizheng Pharmaceutical receiving the highest net inflow of 105 million yuan, followed by Zhejiang Medicine, New Harmony, and Baihua Pharmaceutical with net inflows of 25.71 million yuan, 9.91 million yuan, and 2.14 million yuan respectively [2][3] Group 2 - In terms of fund inflow ratios, Haizheng Pharmaceutical, Zhejiang Medicine, and Baihua Pharmaceutical had the highest net inflow rates of 9.03%, 5.48%, and 2.27% respectively [3] - The trading performance of key stocks in the Artemisinin concept included Haizheng Pharmaceutical with a daily increase of 10.02% and a turnover rate of 9.22%, while Zhejiang Medicine rose by 0.79% with a turnover rate of 3.19% [3][4] - Other stocks such as New Harmony and Baihua Pharmaceutical experienced declines of 1.36% and 0.41% respectively, with turnover rates of 1.04% and 3.34% [3][4]